Emmanuel Androulakis

List of Publications by Year
in descending order

70	1,526	430874	330143
papers	citations	18 h-index	37 g-index

71	71	71	3083
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hypertrophic cardiomyopathy or athlete's heart? A systematic review of novel cardiovascular magnetic resonance imaging parameters. European Journal of Sport Science, 2023, 23, 143-154.	2.7	4
2	Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 288.	2.4	12
3	Spontaneous Coronary Artery Dissection: Insights From Cardiac Magnetic Resonance and Extracoronary Arterial Screening. Circulation, 2022, 145, 555-557.	1.6	3
4	Transcatheter mitral valve repair with MitraClip in patients with pulmonary hypertension: hemodynamic and prognostic perspectives. Reviews in Cardiovascular Medicine, 2021, 22, 33.	1.4	1
5	New Drugs and Interventional Strategies for the Management of Hypertension. Current Pharmaceutical Design, 2021, 27, 1396-1406.	1.9	1
6	Chylopericardium associated with constrictive pericarditis assessed by multimodality imaging. Clinical Case Reports (discontinued), 2021, 9, e04354.	0.5	2
7	Eosinophilic heart disease: diagnostic and prognostic assessment by cardiac magnetic resonance. European Heart Journal Cardiovascular Imaging, 2021, 22, 1273-1284.	1.2	13
8	The Role of Cardiovascular Magnetic Resonance Imaging in the Assessment of Myocardial Fibrosis in Young and Veteran Athletes: Insights From a Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 784474.	2.4	7
9	Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options. Current Pharmaceutical Design, 2020, 26, 5953-5968.	1.9	4
10	Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment. Current Pharmaceutical Design, 2019, 24, 4424-4435.	1.9	10
11	Biological therapies targeting arrhythmias: are cells and genes the answer?. Expert Opinion on Biological Therapy, 2018, 18, 237-249.	3.1	0
12	The Role of Cardiovascular Magnetic Resonance in Sports Cardiology; Current Utility and Future Perspectives. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 86.	0.9	18
13	Statins and Inflammation in Cardiovascular Disease. Current Pharmaceutical Design, 2018, 23, 7027-7039.	1.9	14
14	Statins in Aortic Stenosis. Current Pharmaceutical Design, 2018, 23, 7121-7127.	1.9	0
15	Coronary Artery Atherosclerosis in Hypertensive Patients: The Role of Fibrinogen Genetic Variability. Revista Espanola De Cardiologia (English Ed), 2017, 70, 34-41.	0.6	6
16	Socioeconomic status and risk factors for cardiovascular disease: Impact of dietary mediators. Hellenic Journal of Cardiology, 2017, 58, 32-42.	1.0	131
17	Ateroesclerosis coronaria en pacientes hipertensos: elÂpapel deÂlaÂvariabilidad genÃ©tica delÂfibrinÃ³geno. Revista Espanola De Cardiologia, 2017, 70, 34-41.	1.2	3
18	Reninâ€Angiotensin System Inhibitors vs Other Antihypertensives in Hypertensive Blacks: A Metaâ€Analysis. Journal of Clinical Hypertension, 2017, 19, 344-350.	2.0	9

#	Article	IF	Citations
19	Subclinical Organ Damage in Whiteâ€Coat Hypertension: The Possible Role of Cystatin C. Journal of Clinical Hypertension, 2017, 19, 190-197.	2.0	13
20	High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes. Current Cardiology Reviews, 2017, 13, 168-182.	1.5	9
21	White-coat hypertension and cardiovascular events. Journal of Hypertension, 2016, 34, 593-599.	0.5	131
22	Reply. Journal of Hypertension, 2016, 34, 1658-1659.	0.5	1
23	Statins and myocardial infarction: Type, dose, and administration time: Does it matter?. Trends in Cardiovascular Medicine, 2016, 26, 433-441.	4.9	7
24	Percutaneous Coronary Intervention Rates and Associated Independent Predictors for Progression of Nontarget Lesions in Patients With Diabetes Mellitus After Drug-Eluting Stent Implantation. Angiology, 2016, 67, 10-11.	1.8	0
25	Meta-Analysis of Oral Anticoagulants with Dual versus Single Antiplatelet Therapy in Patients after Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs, 2016, 16, 103-110.	2.2	9
26	HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation. Expert Opinion on Therapeutic Targets, 2016, 20, 907-921.	3.4	11
27	The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Failure Reviews, 2016, 21, 169-176.	3.9	132
28	The Impact of Antiplatelet Treatment on Endothelial Function. Current Pharmaceutical Design, 2016, 22, 4512-4518.	1.9	7
29	Imaging Subclinical Atherosclerosis: Where Do We Stand?. Current Cardiology Reviews, 2016, 13, 47-55.	1.5	17
30	Genetic Polymorphisms and the Vascular Endothelium. , 2015, , 129-142.		2
31	Chronic thromboembolic pulmonary arterial hypertension: a review of the literature and novel therapeutic approaches. Expert Review of Respiratory Medicine, 2015, 9, 351-359.	2.5	0
32	Homoarginine in the shadow of asymmetric dimethylarginine: from nitric oxide to cardiovascular disease. Amino Acids, 2015, 47, 1741-1750.	2.7	33
33	Improving the detection of preclinical organ damage in newly diagnosed hypertension: nocturnal hypertension versus non-dipping pattern. Journal of Human Hypertension, 2015, 29, 689-695.	2.2	23
34	Oxidative Stress and Early Atherosclerosis: Novel Antioxidant Treatment. Cardiovascular Drugs and Therapy, 2015, 29, 75-88.	2.6	48
35	Diabetes Mellitus-Associated Vascular Impairment. Journal of the American College of Cardiology, 2013, 62, 667-676.	2.8	230
36	Combined effects of fibrinogen genetic variability on atherosclerosis in patients with or without stable angina pectoris: Focus on the coagulation cascade and endothelial function. International Journal of Cardiology, 2013, 168, 4602-4607.	1.7	12

#	Article	IF	Citations
37	Inflammation and right ventricle: The hunting of the missing link. International Journal of Cardiology, 2013, 168, 3152-3154.	1.7	4
38	Lp-PLA2â€"A novel marker of atherosclerosis: To treat or not to treat?. International Journal of Cardiology, 2013, 165, 213-216.	1.7	15
39	Effects of the C-344T aldosterone synthase gene variant on preclinical vascular alterations in essential hypertension. International Journal of Cardiology, 2013, 168, 1605-1606.	1.7	6
40	Genetic Predisposition to Left Ventricular Hypertrophy and the Potential Involvement of Cystatin-C in Untreated Hypertension. American Journal of Hypertension, 2013, 26, 683-690.	2.0	8
41	Insight to the Pathophysiology of Stable Angina Pectoris. Current Pharmaceutical Design, 2013, 19, 1593-1600.	1.9	3
42	Heart Rate as a Therapeutic Target in Angina Pectoris. Current Pharmaceutical Design, 2013, 19, 1562-1568.	1.9	0
43	The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque. Current Pharmaceutical Design, 2013, 19, 1651-1657.	1.9	3
44	Heart Rate as a Therapeutic Target in Angina Pectoris. Current Pharmaceutical Design, 2013, 19, 1562-1568.	1.9	4
45	Novel Biomarkers Assessing Endothelial Dysfunction: Role of microRNAs. Current Topics in Medicinal Chemistry, 2013, 13, 1518-1526.	2.1	13
46	Prognostic Role of miRNAs in Coronary Artery Disease. Current Topics in Medicinal Chemistry, 2013, 13, 1540-1547.	2.1	18
47	MicroRNAs in the Diagnosis and Treatment of Unstable Angina. Current Topics in Medicinal Chemistry, 2013, 13, 1596-1604.	2.1	8
48	Antioxidant Treatment and Endothelial Dysfunction: Is it Time for Flavonoids?. Recent Patents on Cardiovascular Drug Discovery, 2013, 8, 81-92.	1.5	22
49	Novel Anti-platelet Agents for the Treatment of Stable Angina Pectoris. Current Pharmaceutical Design, 2013, 19, 1581-1586.	1.9	0
50	Targeting Myocardial Metabolism for the Treatment of Stable Angina. Current Pharmaceutical Design, 2013, 19, 1587-1592.	1.9	0
51	Stable Angina Pectoris: Current Medical Treatment. Current Pharmaceutical Design, 2013, 19, 1569-1580.	1.9	1
52	The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque. Current Pharmaceutical Design, 2013, 19, 1651-1657.	1.9	2
53	Novel Biomarkers Used in the Assessment of Acute Coronary Syndrome. , 2013, , 345-362.		0
54	C-Reactive Protein in Cardiovascular Disease. , 2013, , 3-18.		0

#	Article	IF	Citations
55	Clinical Utility of Biomarkers in Premature Atherosclerosis. Current Medicinal Chemistry, 2012, 19, 2521-2533.	2.4	19
56	Lifestyle Factors and Endothelial Function. Current Vascular Pharmacology, 2012, 10, 94-106.	1.7	9
57	Genetic polymorphism M235T of angiotensinogen: Effects on endothelial function and arterial stiffness in hypertensives. International Journal of Cardiology, 2012, 155, 501-503.	1.7	6
58	Novel Therapeutic Approaches Targeting Matrix Metalloproteinases in Cardiovascular Disease. Current Topics in Medicinal Chemistry, 2012, 12, 1214-1221.	2.1	21
59	Novel therapeutic strategies in the management of arterial hypertension. , 2012, 135, 168-175.		13
60	Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies. Heart Failure Reviews, 2012, 17, 65-79.	3.9	22
61	The Role of Matrix Metalloproteinases in Essential Hypertension. Current Topics in Medicinal Chemistry, 2012, 12, 1149-1158.	2.1	16
62	Matrix Metalloproteinases in Acute Coronary Syndromes: Current Perspectives. Current Topics in Medicinal Chemistry, 2012, 12, 1192-1205.	2.1	20
63	Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease. Current Topics in Medicinal Chemistry, 2012, 12, 1206-1213.	2.1	9
64	Fibrinogen and cardiovascular disease: Genetics and biomarkers. Blood Reviews, 2011, 25, 239-245.	5.7	64
65	Pathophysiology of Atherosclerosis: The Role of Inflammation. Current Pharmaceutical Design, 2011, 17, 4089-4110.	1.9	96
66	Inflammation in Hypertension: Current Therapeutic Approaches. Current Pharmaceutical Design, 2011, 17, 4121-4131.	1.9	31
67	Inflammatory Markers in Essential Hypertension: Potential Clinical Implications. Current Vascular Pharmacology, 2010, 8, 509-516.	1.7	46
68	From Atherosclerosis to Acute Coronary Syndromes: The Role of Soluble CD40 Ligand. Trends in Cardiovascular Medicine, 2010, 20, 153-164.	4.9	36
69	Novel therapeutic strategies targeting vascular endothelium in essential hypertension. Expert Opinion on Investigational Drugs, 2010, 19, 1395-1412.	4.1	12
70	Essential Hypertension. Cardiology in Review, 2009, 17, 216-221.	1.4	76